How a four-month FDA delay forced a small biotech company to close its doors Kezar Life Sciences, developing a rare disease drug, blames agency dysfunction By Elaine ChenApril 6, 2026

How a four-month FDA delay forced a small biotech company to close its doors Kezar Life Sciences, developing a rare disease drug, blames agency dysfunction By Elaine ChenApril 6, 2026 Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech. https://www.statnews.com/2026/04/06/fda-delay-cited-in-closure-kezar-life-sciences-biotech-startup/